Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:CMPX NASDAQ:ETON NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$489.87M2.39516,680 shs644,225 shsCMPXCompass Therapeutics$3.57+1.1%$3.10$1.27▼$4.08$488.14M1.5968,618 shs593,713 shsETONEton Pharmaceuticals$17.65+0.5%$16.06$4.82▼$21.48$471.19M1.1219,200 shs169,126 shsTARAProtara Therapeutics$3.14-1.9%$3.15$1.60▼$10.48$123.46M1.52143,277 shs157,702 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%-2.97%-9.93%+39.90%-17.45%CMPXCompass Therapeutics0.00%+3.78%+21.02%+48.13%+138.00%ETONEton Pharmaceuticals0.00%-0.11%+5.69%+23.43%+268.48%TARAProtara Therapeutics0.00%-0.32%-1.57%0.00%+84.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.32-4.0%$15.38$8.04▼$25.88$489.87M2.39516,680 shs644,225 shsCMPXCompass Therapeutics$3.57+1.1%$3.10$1.27▼$4.08$488.14M1.5968,618 shs593,713 shsETONEton Pharmaceuticals$17.65+0.5%$16.06$4.82▼$21.48$471.19M1.1219,200 shs169,126 shsTARAProtara Therapeutics$3.14-1.9%$3.15$1.60▼$10.48$123.46M1.52143,277 shs157,702 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics0.00%-2.97%-9.93%+39.90%-17.45%CMPXCompass Therapeutics0.00%+3.78%+21.02%+48.13%+138.00%ETONEton Pharmaceuticals0.00%-0.11%+5.69%+23.43%+268.48%TARAProtara Therapeutics0.00%-0.32%-1.57%0.00%+84.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57191.98% UpsideCMPXCompass Therapeutics 3.10Buy$12.89261.03% UpsideETONEton Pharmaceuticals 3.00Buy$29.6768.08% UpsideTARAProtara Therapeutics 3.17Buy$19.60524.20% UpsideCurrent Analyst Ratings BreakdownLatest TARA, ARCT, CMPX, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.008/12/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.008/12/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$32.00 ➝ $35.007/1/2025CMPXCompass TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$9.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.09N/AN/A$8.90 per share1.95CMPXCompass Therapeutics$850K580.78N/AN/A$0.91 per share3.92ETONEton Pharmaceuticals$58.18M8.14N/AN/A$0.94 per share18.78TARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A35.30N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)Latest TARA, ARCT, CMPX, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90CMPXCompass TherapeuticsN/A7.667.66ETONEton Pharmaceuticals1.141.771.16TARAProtara TherapeuticsN/A12.8112.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CMPXCompass Therapeutics68.43%ETONEton Pharmaceuticals27.86%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%CMPXCompass Therapeutics29.80%ETONEton Pharmaceuticals16.03%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million22.65 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableTARAProtara Therapeutics3038.58 million35.34 millionOptionableTARA, ARCT, CMPX, and ETON HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Sells 244,810 Shares of Protara Therapeutics, Inc. $TARASeptember 3, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comVelan Capital Investment Management LP Buys 88,800 Shares of Protara Therapeutics, Inc. $TARAAugust 31, 2025 | marketbeat.comProtara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comCantor Fitzgerald Brokers Raise Earnings Estimates for TARAAugust 22, 2025 | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from BrokeragesAugust 20, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TARA Q3 EarningsAugust 16, 2025 | marketbeat.comWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13, 2025 | finance.yahoo.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comProtara Beats Q2 Loss EstimatesAugust 11, 2025 | aol.comAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30, 2025 | globenewswire.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of DirectorsJune 23, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTARA, ARCT, CMPX, and ETON Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$17.32 -0.72 (-3.99%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.14 -0.18 (-1.01%) As of 09/12/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Compass Therapeutics NASDAQ:CMPX$3.57 +0.04 (+1.13%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.56 -0.01 (-0.42%) As of 09/12/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$17.65 +0.08 (+0.46%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.65 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Protara Therapeutics NASDAQ:TARA$3.14 -0.06 (-1.88%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.14 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
